New drug targets tough cancers in 401-Patient trial
NCT ID NCT07417189
First seen Feb 20, 2026 · Last updated May 01, 2026 · Updated 5 times
Summary
This study tests a new drug, ABSK141, in about 401 adults with advanced solid tumors that have a specific gene change called KRAS G12D. The goal is to find the best dose and check if it is safe and works against cancers like colorectal, lung, and pancreatic cancer. Participants will take the drug by mouth and be monitored for side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 201321, China
Contact
Conditions
Explore the condition pages connected to this study.